Alpha – Resource KT Thu, 16 Sep 2021 03:18:09 +0000 en-US hourly 1 Alpha – Resource KT 32 32 Alpha Architect Etf – Alpha Architect Value Momentum Trend ETF (VMOT) gains 1.30% on moderate volume on September 15th Thu, 16 Sep 2021 01:40:00 +0000

Today, Alpha Architect Etf Trust – Alpha Architect Value Momentum Trend ETF Inc (CBOE: VMOT) stock gained $ 0.366, an increase of 1.30%. Alpha Architect Etf – The Alpha Architect Value Momentum Trend ETF opened at $ 28.23 before trading between $ 28.59 and $ 28.23 throughout Wednesday’s session. The activity saw the market cap of Alpha Architect Etf – Alpha Architect Value Momentum Trend ETF rise to $ 48,897,450 on 341 stocks – below their 30-day average of 4,062.

Visit Alpha Architect Etf Trust – Alpha Architect Value Momentum Trend ETF for more information.

About CBOE Global Markets

CBOE operates the largest options exchange and the third largest in the United States. volume.

To get more information on Alpha Architect Etf Trust – Alpha Architect Value Momentum Trend ETF and keep up with the latest company updates, you can visit the Company Profile page here: Alpha Architect Etf Trust – Alpha Architect Value Momentum Trend ETF’s Profile. For more information on the financial markets, be sure to visit Equities News. Also, don’t forget to sign up for the Daily Fix to get the best stories delivered to your inbox 5 days a week.

Sources: The chart is provided by TradingView based on 15 minute lag prices. All other data is provided by IEX Cloud as of 8:05 p.m. ET on the day of publication.

The views and opinions expressed in this article are those of the authors and do not represent the views of Readers should not take the author’s statements as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please visit:

Consumer Brands Association urges White House for clarity on vaccine mandates

Freshworks targets $ 9 billion IPO valuation in the upper deposit range

Fauci supports mandate of COVID-19 vaccine for all domestic air travel

Unemployment claims drop to 310,000 – lowest in nearly 18 months

200 Westerners on a Qatar Airways flight from Kabul

Pennsylvania Republican lawmakers launch election integrity inquiry

President Biden and Congressional Democrats push for civilian climate body

Biden administration to unveil plan to cut prescription drug prices under Medicare

Uncertainty in Guinea after the military coup that rules out Alpha Condé | Guinea News Sat, 11 Sep 2021 20:08:00 +0000

Guinean leader Alpha Condé used to tell journalists that he was the only one who could run the country. He would also say that the military would not overthrow him.

Sunday, he was wrong.

An elite special forces unit stormed the presidential palace in the capital, Conakry, detaining the 83-year-old president. A few hours later, the coup leader, Colonel Mamady Doumbouya, appeared on state television station Radio Télévision Guinéenne, draped in the Guinean flag, presenting himself to the surprised Guineans as the country’s new leader.

The coup in Guinea left the country in limbo, prompted the threat of sanctions from the West African economic bloc and saw the price of aluminum reach its highest level in more than a decade. Guinea is the world’s largest producer of bauxite, a mineral used to make aluminum.

Regional leaders immediately condemned the seizure of power, urging the coup plotters to restore constitutional order and release Condé.

In Conakry, the new military leaders were quick to try to reassure the political and economic players of their good intentions.

A government of national unity would be put in place to lead the transition to civilian rule, Doumbouya told members of the overthrown government on Monday.

The new management would honor mining contracts, urging companies to continue operating, he said. The land and sea borders that were closed at the time of the takeover reopened in less than 24 hours.

However, this did not convince the regional bloc of the Economic Community of West African States (ECOWAS), which suspended Guinea from all its decision-making bodies. Two days later, the African Union followed suit.

Condé became Guinea’s first democratically elected leader in 2010, his victory seen as ending decades of authoritarian rule by the country’s two first presidents, Sékou Touré and Lansana Conté, who served for 26 and 24 respectively. years.

Condé was re-elected for a second term in 2015. But he became increasingly hated when he passed a constitutional referendum, backed by Russia, which, according to Condé, saw him run for a controversial third term in of the October 2020 elections, which he won.

Sidy Yansane, journalist and analyst in Conakry, said Condé caused the fall himself.

“Condé was very unpopular, although people still voted for him. With the third term, Condé has gone too far, ”he said by telephone.

Questions are looming

In his address to the nation on Sunday, Doumbouya said Condé’s impeachment was necessary and went on to blame his leaders for Guinea’s poverty, corruption, bad government and lack of development. Doumbouya said reform of the country’s system of government and institutions was desperately needed.

“If you see the state of our roads, of our hospitals, you realize that it is time for us to wake up,” said Doumbouya. What he did not say is when a transitional government could be put in place.

“Right now people are just happy to see Condé gone,” Yansane said. “But very soon they will need to see actions from the junta; signs that things are about to change, including a timeline for a transition.

Residents cheer on army soldiers after the uprising that led to the overthrow of President Alpha Condé in the Kaloum neighborhood of Conakry, Guinea [File: Souleymane/Reuters] Camara

So far, Sunday’s coup has met with minimal resistance. Jubilant crowds greeted the coup plotters as they passed through Conakry earlier this week.

Sally Bilaly Sow, blogger and activist, 29, said the coup could be an opportunity to reform and restructure state institutions.

“The important thing now is not to rush. To give an interim leadership enough time for reforms and to prepare for new elections, ”Sow said by phone from Conakry.

Cellou Dalein Diallo, Condé’s lone challenger in the opposition boycotted 2020 polls, said he was open to participating but would not set an end date for a transition and return to civilian rule.

The coup in Guinea is the fourth military takeover in West Africa this year after two coups d’état in neighboring Mali – the second in May – and a questionable succession in Chad raising fears of a democratic retreat in the country. the region.

In Mali, the army-led interim government is behind an 18-month schedule for general elections that are expected to return the country to civilian rule.

In Chad, President Mahamat Deby, who succeeded his father Idriss Deby in April, does not seem in a rush to hand power over to a civilian government.

An ECOWAS delegation that visited Conakry on Friday said its first encounters with the coup plotters had been “positive”.

The delegation also met Conde, said ECOWAS Commission President Jean-Claude Kassi Brou, calling the ousted leader a “former president” indicating that the regional bloc would not call for his reinstatement.

A-Alpha Bio start-up tackles a major protein problem facing large pharmaceutical companies Wed, 08 Sep 2021 23:17:12 +0000

Pharmaceutical and biotech companies looking for new drugs are doing tests along the way to see how proteins interact. Analysis of the protein-protein interaction can reveal how cells communicate, how genes are regulated, and how the immune system identifies and attacks disease, said David Younger, co-founder and CEO of A-Alpha Bio. It is a necessary process but it takes time. For businesses large and small, this usually means testing one protein interaction at a time.

A-Alpha Bio’s technology allows millions of protein interactions to be tested simultaneously. The Seattle-based startup already has a handful of biotech industry partners. She now has $ 20 million to expand the capabilities of the technology and grow the business. The Series A funding round announced on Wednesday was led by Madrona Venture Group; Perceptive Xontogeny Venture Fund and Lux ​​Capital have also invested.

A-Alpha Bio is part of the growing contingent in proteomics, the large-scale study of proteins. This area has become a hot zone for investment. Nautilus Biotechnology was recently made public in a merger deal that earned it $ 350 million. The Seattle-based company technology produces protein landscape maps that provide insight into disease pathways and progression. Seer, based in Redwood City, Calif., Raised $ 55 million last year to support the development of its protein analysis platform. As these companies detect proteins in a sample, Younger said that A-Alpha Bio is working in a different area of ​​proteomics, finding out which proteins bind to each other.

The startup’s approach begins with yeast, the same yeast that is used to make bread and beer. Yeast cells are frequently used in scientific experiments because they have some similarities to human cells and they are highly manipulable. A-Alpha Bio’s technology, called AlphaSeq, is a lab method the company developed to use genetically engineered yeast cells to test millions of protein interactions at the same time.

The methods traditionally used to test for protein interactions come with tradeoffs between quantity and quality, Younger said. To get high-quality results, scientists test two proteins in one experiment. This approach is not scalable. If quantity is the goal, technology platforms from companies such as Adimab and Distributed Bio analyze a large number of proteins. But every measure is shoddy, Younger said.

AlphaSeq was developed to deliver quality and quantity in the same test. The company has focused its research in two areas: the discovery of antibodies and the identification of targets for molecular glues, which are a key part of an emerging therapeutic approach called targeted protein degradation. A-Alpha Bio partners with pharmaceutical companies to help them discover these targets. Publicly disclosed partners include Twist Biopharma, which is a division of South San Francisco-based Twist Bioscience, and Seattle-based Lumen Bioscience.

Younger did not set out to make better antibodies or molecular glues. A-Alpha Bio’s roots stretch back almost a decade to his days as a graduate student at the Institute for Protein Design and the Center for Synthetic Biology at the University of Washington. At the time, he was trying to solve a problem that he and many of his peers were facing. Using computers, it is common for a student to design up to a thousand proteins in a week, or even in a single day.

“Because of the maturity of computer protein design, it has come a long way,” Younger said. “But you still have to test them. This is the bottleneck. It is impossible to test all of these proteins.

Young’s graduate work consisted of developing the platform that would become AlphaSeq. As the research progressed, he was faced with the question of how to maximize his impact. Publishing an article would make the research available for others to pursue. He also thought of laying off research at a company. He chooses a third option: to start a business.

A-Alpha Bio was formed in 2017. The following year, the startup received its first research grant for innovation in small businesses, a phase 1 award for the development of a profiling platform. of drugs using yeast cells. The company’s focus on antibodies and molecular glues stems from the client discovery component of grant preparation. Younger said he and his team had been pressured to go out and talk to as many experts in the pharmaceutical industry as possible to identify the needs of the market. In the case of antibodies, the problem Younger has heard over and over again is that a company may have thousands of drug candidates, but their tools allow them to select only one at a time. Therefore, maybe 10 or less antibodies undergo full testing, as it is simply not possible to test all of them.

Molecular glues are a new area of ​​research for industry as the targeted degradation of proteins is still a new area of ​​research. The technology involves tagging a disease-causing protein for removal by the cell’s integrated machinery to get rid of old or damaged proteins. The challenge is that not all proteins have the affinity to stick to the molecular tag that marks a protein for elimination. This is where molecular glue comes in. A-Alpha Bio received a Phase II grant last year to develop its molecular glue discovery technology.

At the moment, A-Alpha Bio’s technology supports drug research from larger partners. The startup receives an upfront payment under agreements that also commit milestone payments and, when therapy commercializes, royalties on sales. Going forward, Younger sees A-Alpha Bio using its technology to create an internal drug pipeline. In the shorter term, A-Alpha Bio’s research could contribute to the development of drugs against Covid-19. The startup is looking for antibodies that can bind to SARS-CoV-2, research with Lumen supported by a grant from the Bill & Melinda Gates Foundation. A year ago, A-Alpha Bio received a Phase 1 SBIR grant to develop an antibody generation platform for coronavirus variants.

The ability to test millions of protein interactions means that AlphaSeq produces a lot of data. Younger said the next steps for A-Alpha Bio include building capacity to analyze this data. The company aims to use machine learning techniques to predict how proteins interact. Over the next 18-24 months, Younger expects the startup’s workforce of 13 to grow to 50, with many of those hires joining the machine learning and data science team, led by Ryan. Emerson, an adaptive biotechnology veteran.

“Over time, we will accumulate the greatest repository of protein interactions,” Younger said. “As we build this database, we can use tools like machine learning to start making engineered protein interactions a computational problem rather than an experimental problem. “

Photo by Flickr user Roger W via Creative Commons license

Photos: Lake George Alpha 70.3 Triathlon Race Sat, 04 Sep 2021 17:24:30 +0000

September 4, 2021 – The sun had yet to rise over French Mountain when the first wave of swimmers plunged into Lake George for the start of the weekend’s first Alpha Win race, the Alpha 70.3, a 1.2 mile swim triathlon, 90 km bike path and half marathon. The races continue on Sunday September 5th with the Alpha Sprint and the Alpha Olympic.

According to Chris Pace of Alpha Win, more than 600 athletes are competing in Lake George this year, which he says is a great turnout given the challenges and travel restrictions competitors face exiting the pandemic.

Alpha Win, formerly HITS Endurance, is led by Tommy Struzzieri. The organization offers races to include athletes with different levels of training and endurance. “A distance for all” is the company’s slogan.

Tommy struzzieri

The grounds of Lake George Battlefield Park along Beach Road serve as base camp.